Akebia Therapeutics Expands Vafseo Market at Healthcare Conference

Akebia Therapeutics ( (AKBA) ) just unveiled an update.

Akebia Therapeutics announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, where it plans to present its strategy and business outlook, including the recent U.S. launch of Vafseo for anemia in dialysis patients. The company has secured contracts covering nearly 100% of U.S. dialysis patients and aims to expand Vafseo’s label to include late-stage non-dialysis CKD patients, targeting a billion-dollar market opportunity. Akebia expects its current cash resources to support operations for at least two years, despite uncertainties about future funding.

More about Akebia Therapeutics

Akebia Therapeutics is a commercial-stage company focused on developing treatments for kidney disease, particularly through its hypoxia-inducible factor (HIF)-based platform. The company markets Vafseo, a treatment for anemia due to chronic kidney disease (CKD) in adult dialysis patients, and is expanding its pipeline to address other kidney and rare diseases.

YTD Price Performance: -7.89%

Average Trading Volume: 2,182,124

Technical Sentiment Consensus Rating: Sell

Current Market Cap: $381.8M

Find detailed analytics on AKBA stock on TipRanks’ Stock Analysis page.